3,4-diaminopyridine


Also found in: Wikipedia.

3,4-diaminopyridine

a parasympathomimetic agent, similar to 4-aminopyridine.
Mentioned in ?
References in periodicals archive ?
Zesiewicz of the University of South Florida in Tampa, found that they could not recommend leve-tiracetam and 3,4-diaminopyridine as second-line agents, based on quality (level B) clinical evidence that they do not reduce limb tremor.
Zesiewicz of the University of South Florida in Tampa, found that they could not recommend levetiracetam and 3,4-diaminopyridine as second-line agents, based on quality (level B) clinical evidence that they do not reduce limb tremor.
This trial used Fampridine's chemical cousin, 3,4-diaminopyridine.
6 January 2010 - US-based biopharmaceutical company BioMarin Pharmaceutical Inc (NASDAQ: BMRN) announced yesterday that the European Commission has granted marketing approval for 3,4-diaminopyridine (amifampridine phosphate), for the rare autoimmune disease Lambert Eaton Myasthenic Syndrome (LEMS).
along with the rights to a proprietary form of 3,4-diaminopyridine, amifampridine phosphate, an experimental treatment for Lambert Eaton Myasthenic Syndrome (LEMS).
Studies have also been conducted with the potassium channel blockers 4-aminopyridine and 3,4-diaminopyridine (neither is currently marketed in the United States).
30 November 2009 - US-based BioMarin Pharmaceutical Inc (NASDAQ: BMRN) said today that the US Food and Drug Administration (FDA) has granted Orphan Drug designation for 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate, for Lambert Eaton Myasthenic Syndrome (LEMS).
The aminopyridines (4-aminopyridine [AP] and 3,4-diaminopyridine [DAP]) are potassium channel blockers shown to improve nerve conduction in experimentally demyelinated axons.

Full browser ?